Bone-targeting liposome formulation of Salvianic acid A accelerates the healing of delayed fracture Union in Mice

Yanzhi Liu, Zhenshan Jia, Mohammed P. Akhter, Xiang Gao, Xiaobei Wang, Xiaoyan Wang, Gang Zhao, Xin Wei, You Zhou, Xiuli Wang, Curtis W. Hartman, Edward V. Fehringer, Liao Cui, Dong Wang

Research output: Contribution to journalArticle

Abstract

Delayed fracture union is a significant clinical challenge in orthopedic practice. There are few non-surgical therapeutic options for this pathology. To address this challenge, we have developed a bone-targeting liposome (BTL) formulation of salvianic acid A (SAA), a potent bone anabolic agent, for improved treatment of delayed fracture union. Using pyrophosphorylated cholesterol as the targeting ligand, the liposome formulation (SAA-BTL) has demonstrated strong affinity to hydroxyapatite in vitro, and to bones in vivo. Locally administered SAA-BTL was found to significantly improve fracture callus formation and micro-architecture with accelerated mineralization rate in callus when compared to the dose equivalent SAA, non-targeting SAA liposome (SAA-NTL) or no treatment on a prednisone-induced delayed fracture union mouse model. Biomechanical analyses further validated the potent therapeutic efficacy of SAA-BTL. These results support SAA-BTL formulation, as a promising therapeutic candidate, to be further developed into an effective and safe clinical treatment for delayed bone fracture union.

LanguageEnglish (US)
Pages2271-2282
Number of pages12
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume14
Issue number7
DOIs
StatePublished - Oct 1 2018

Fingerprint

Fracture Healing
Mammals
Computer architecture
Liposomes
Computer Systems
Durapatite
Hydroxyapatite
Bone
Bone and Bones
Acids
Bony Callus
Therapeutics
Anabolic Agents
Bone Fractures
Prednisone
Cholesterol
Orthopedics
Pathology
Ligands

All Science Journal Classification (ASJC) codes

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Cite this

Bone-targeting liposome formulation of Salvianic acid A accelerates the healing of delayed fracture Union in Mice. / Liu, Yanzhi; Jia, Zhenshan; Akhter, Mohammed P.; Gao, Xiang; Wang, Xiaobei; Wang, Xiaoyan; Zhao, Gang; Wei, Xin; Zhou, You; Wang, Xiuli; Hartman, Curtis W.; Fehringer, Edward V.; Cui, Liao; Wang, Dong.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 14, No. 7, 01.10.2018, p. 2271-2282.

Research output: Contribution to journalArticle

Liu, Y, Jia, Z, Akhter, MP, Gao, X, Wang, X, Wang, X, Zhao, G, Wei, X, Zhou, Y, Wang, X, Hartman, CW, Fehringer, EV, Cui, L & Wang, D 2018, 'Bone-targeting liposome formulation of Salvianic acid A accelerates the healing of delayed fracture Union in Mice' Nanomedicine: Nanotechnology, Biology, and Medicine, vol. 14, no. 7, pp. 2271-2282. https://doi.org/10.1016/j.nano.2018.07.011
Liu, Yanzhi ; Jia, Zhenshan ; Akhter, Mohammed P. ; Gao, Xiang ; Wang, Xiaobei ; Wang, Xiaoyan ; Zhao, Gang ; Wei, Xin ; Zhou, You ; Wang, Xiuli ; Hartman, Curtis W. ; Fehringer, Edward V. ; Cui, Liao ; Wang, Dong. / Bone-targeting liposome formulation of Salvianic acid A accelerates the healing of delayed fracture Union in Mice. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2018 ; Vol. 14, No. 7. pp. 2271-2282.
@article{ab41a275e1f548ff8bb1b72de802e98c,
title = "Bone-targeting liposome formulation of Salvianic acid A accelerates the healing of delayed fracture Union in Mice",
abstract = "Delayed fracture union is a significant clinical challenge in orthopedic practice. There are few non-surgical therapeutic options for this pathology. To address this challenge, we have developed a bone-targeting liposome (BTL) formulation of salvianic acid A (SAA), a potent bone anabolic agent, for improved treatment of delayed fracture union. Using pyrophosphorylated cholesterol as the targeting ligand, the liposome formulation (SAA-BTL) has demonstrated strong affinity to hydroxyapatite in vitro, and to bones in vivo. Locally administered SAA-BTL was found to significantly improve fracture callus formation and micro-architecture with accelerated mineralization rate in callus when compared to the dose equivalent SAA, non-targeting SAA liposome (SAA-NTL) or no treatment on a prednisone-induced delayed fracture union mouse model. Biomechanical analyses further validated the potent therapeutic efficacy of SAA-BTL. These results support SAA-BTL formulation, as a promising therapeutic candidate, to be further developed into an effective and safe clinical treatment for delayed bone fracture union.",
author = "Yanzhi Liu and Zhenshan Jia and Akhter, {Mohammed P.} and Xiang Gao and Xiaobei Wang and Xiaoyan Wang and Gang Zhao and Xin Wei and You Zhou and Xiuli Wang and Hartman, {Curtis W.} and Fehringer, {Edward V.} and Liao Cui and Dong Wang",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.nano.2018.07.011",
language = "English (US)",
volume = "14",
pages = "2271--2282",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Bone-targeting liposome formulation of Salvianic acid A accelerates the healing of delayed fracture Union in Mice

AU - Liu, Yanzhi

AU - Jia, Zhenshan

AU - Akhter, Mohammed P.

AU - Gao, Xiang

AU - Wang, Xiaobei

AU - Wang, Xiaoyan

AU - Zhao, Gang

AU - Wei, Xin

AU - Zhou, You

AU - Wang, Xiuli

AU - Hartman, Curtis W.

AU - Fehringer, Edward V.

AU - Cui, Liao

AU - Wang, Dong

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Delayed fracture union is a significant clinical challenge in orthopedic practice. There are few non-surgical therapeutic options for this pathology. To address this challenge, we have developed a bone-targeting liposome (BTL) formulation of salvianic acid A (SAA), a potent bone anabolic agent, for improved treatment of delayed fracture union. Using pyrophosphorylated cholesterol as the targeting ligand, the liposome formulation (SAA-BTL) has demonstrated strong affinity to hydroxyapatite in vitro, and to bones in vivo. Locally administered SAA-BTL was found to significantly improve fracture callus formation and micro-architecture with accelerated mineralization rate in callus when compared to the dose equivalent SAA, non-targeting SAA liposome (SAA-NTL) or no treatment on a prednisone-induced delayed fracture union mouse model. Biomechanical analyses further validated the potent therapeutic efficacy of SAA-BTL. These results support SAA-BTL formulation, as a promising therapeutic candidate, to be further developed into an effective and safe clinical treatment for delayed bone fracture union.

AB - Delayed fracture union is a significant clinical challenge in orthopedic practice. There are few non-surgical therapeutic options for this pathology. To address this challenge, we have developed a bone-targeting liposome (BTL) formulation of salvianic acid A (SAA), a potent bone anabolic agent, for improved treatment of delayed fracture union. Using pyrophosphorylated cholesterol as the targeting ligand, the liposome formulation (SAA-BTL) has demonstrated strong affinity to hydroxyapatite in vitro, and to bones in vivo. Locally administered SAA-BTL was found to significantly improve fracture callus formation and micro-architecture with accelerated mineralization rate in callus when compared to the dose equivalent SAA, non-targeting SAA liposome (SAA-NTL) or no treatment on a prednisone-induced delayed fracture union mouse model. Biomechanical analyses further validated the potent therapeutic efficacy of SAA-BTL. These results support SAA-BTL formulation, as a promising therapeutic candidate, to be further developed into an effective and safe clinical treatment for delayed bone fracture union.

UR - http://www.scopus.com/inward/record.url?scp=85051681034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051681034&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2018.07.011

DO - 10.1016/j.nano.2018.07.011

M3 - Article

VL - 14

SP - 2271

EP - 2282

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

T2 - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 7

ER -